Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.56 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.39 |
| ▸ | IL6 | P05231 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14971446 | 0.92 | LTA4H (0.65) | LTA4HPAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL6051629 | 0.83 | RAB9A (0.41) | LTA4HKDM4ETLR7NPC1RAB9A | |
| SCHEMBL49317 | 0.82 | PAX8 (0.53) | LTA4HPAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL1318906 | 0.80 | RAB9A (0.41) | LTA4HALDH1A1KDM4ETLR7NPC1 | |
| SCHEMBL29106791 | 0.79 | TLR7 (0.44) | LTA4HALDH1A1KDM4ETLR7NPC1 | |
| SCHEMBL16086043 | 0.78 | PIN1 (0.43) | PAX8MEN1KMT2AKDM4ENPC1 | |
| SCHEMBL1639470 | 0.78 | KDM4E (0.50) | LTA4HPAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL11859472 | 0.77 | MEN1 (0.53) | LTA4HPAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL32688290 | 0.77 | MEN1 (0.53) | LTA4HPAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL10642577 | 0.77 | CYP1A2 (0.47) | LTA4HGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781511-B1 | HYDROXY GROUP PROTECTING AGENT AND HYDROXY GROUP PROTECTION METHOD | UNIV NAT CORP KANAZAWA (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9126954-B2 | Hydroxy group protecting agent and hydroxy group protection method | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140343281-A1 | HYDROXY GROUP PROTECTING AGENT AND HYDROXY GROUP PROTECTION METHOD | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343281-A1 | HYDROXY GROUP PROTECTING AGENT AND HYDROXY GROUP PROTECTION METHOD | OGG1, HAO2, HAAO | LTA4H 490/4885PAX8 2464/4885MEN1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.